期刊文献+

沙格列汀治疗初诊伴超重或肥胖的2型糖尿病患者疗效观察 被引量:3

下载PDF
导出
摘要 选取体重超重或肥胖的初诊2型糖尿病患者108例,给予沙格列汀治疗12周,分析治疗前后患者体重、体重指数、血压、血糖、糖化血红蛋白、C肽水平及低密度脂蛋白胆固醇等生化指标的变化。结果治疗后,患者体重、体重指数、腹围、血压水平、空腹及餐后C肽水平、糖化血红蛋白及低密度脂蛋白胆固醇较前下降,但无统计学差异(P>0.05);患者空腹血糖、早餐后2小时血糖水平较前下降,差异具有统计学意义(P<0.05);治疗期间无明确低血糖事件发生。结论沙格列汀治疗体重超重或肥胖的初诊2型糖尿病患者安全有效,而且对血压、血脂等代谢指标也有改善作用。
出处 《实用糖尿病杂志》 2013年第3期36-38,共3页 Journal of Practical Diabetology
  • 相关文献

参考文献4

  • 1Yang WY, Lu JM, Weng JP, et al. Prevalence of Diabetes a- mong Men and Women in China. N Engl J Med 2010;25 ;362(12) : 1090 - 1101.
  • 2中华医学会糖尿病学分会.中国2型糖尿病防治指南[J].中华内分泌代谢杂志,2011,27(12):s12b1-s12b36.
  • 3Drouin P, Blickle JF,Charbonnel B, et al. Diagnosis and classi- fication of diabetes meUitus;the new criteria. Diabetes Metab 1999; 25:72 - 83.
  • 4刘烨,洪天配.DPP-4抑制剂与二甲双胍联合治疗的合理性及其研究证据[J].中华内分泌代谢杂志,2012,28(12):1033-1035. 被引量:18

二级参考文献28

  • 1Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metfonnin. Diabetes Care, 2007,30 ;890- 895.
  • 2Defronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metfonnin alone. Diabetes Care, 2009,32;1649-1655.
  • 3Gallwitz B, RosenstockJ, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin , a randomised, double-blind, non-inferiority trial. Lancet, 2012,380 ;475483.
  • 4Haak T, Meinicke T,Jones R, et al. Initial combination of linagliptin and metfonnin improves glycaemic control in type 2 diabetes; a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab,2012,14;565-574.
  • 5Reasner C, Olansky L, Seck TL, et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metfonnin compared with metfonnin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab, 2011,13 ;644-652.
  • 6Seck T, Engel S, Golm G, et al. Initial Therapy with the Fixed-Dose Combination ( FDC) of Sitagliptin and Metfonnin (JANUMET?) in Patients with Type 2 Diabetes Mellitus ( T2DM) Provided Superior Glycemic Control vs. Metfonnin Alone, Based on the AACEI ACE Diabetes Algorithm. 2011. Diabetes, 2011 ,60 ( Suppl 1 ) ; A290.
  • 7Charles MA, Eschwege E. Prevention of type 2 diabetes; role of metfonnin. Drugs, 1999,58(Suppll) ;71-73,75-82.
  • 8Asmar M, HolstJ1. Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide; new advances. CUIT Opin Endocrinol Diabetes Obes , 2010, 17 ; 57 -62.
  • 9Thondam SK, Cross A, Cuthbertson DJ, et al. Effects of chronic treatment with metfonnin on dipeptidyl peptidase4 activity, glucagon?like peptide I and ghrelin in obese patients with Type 2 diabetes mellitus. Diabet Med, 2012,29; e205-e21O.
  • 10Mannucci E, Tesi F, Bardini G, et al. Effects of metfonnin on glucagon-like peptide-I levels in obese patients with and without Type 2 diabetes. Diabetes Nutr Metab, 2004,17 ;336-342.

共引文献20

同被引文献24

  • 1Rasmussen H B, Branner S,Wiberg F C,et al. Crystal structure of human dipeptidyl peptidase 1V/CD26 in complex with a substrate analog[ J]. Nat Struct Biol,2003,10( 1 ) :19.
  • 2Aschner P,Kipnes M S,Lunceford J K,et al. Effect of the dipeptidyl peptidase- 4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes [ J 1. Diabetes Care ,2006,29 ( 12 ) :2632.
  • 3Barnett A. DPP - 4 inhibitors and their potential role in the management of type 2 diabetes [ J ]. Int Clin Pract,2006,60 ( 11 ) : 1454.
  • 4Ristic S, Byiers S, Foley J,et al. Improved glycemic control with dipepti- dyl peptidase -4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response[ J]. Diabetes Obes Metab ,2005,7 (6):692.
  • 5Rosenstock J, Aguilar - Salinas C, Klein E,et al. Effect of saxagliptin inonotherapy in treatment- naive patients with type 2 diabetes[ J]. Curr Med Res 0oin.2009,25 (1) :2401.
  • 6DeFronzo R A,Fleck P R,Wilson C A,et al. Efficacy and safety of the dipeptidy[ peptidase - 4 inhibitor alogliptin in patients with type 2 diabe- tes and inadequate glyeemic control: a randomized, double - blind, pla- cebo - controlled study [ J ]. Diabetes Care,2008,31 ( 12 ) :2315.
  • 7Prattey R E, Kipnes M S, Fleck P R,et al. Efficacy and safety of the dipeptidyl peptidase - 4 inhibitor alogliptin in patients with type 2 diabe- tes inadequately controlled by glyburide monotherapy [ J ]. Diabetes Obes Metab,2009,11 ( 2 ) : 167.
  • 8Del Prato S, Barnett A H,Huisman H,et al. Effect of linagliptin mono- therapy on glycaemic control and markers of - celt function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial[ J. Diabetes Obes Metab,2011,13 ( 3 ) :258.
  • 9Forst T, Uhlig - Laske B, Ring A,et al. Linagliptin ( BI 1356 ) , a potent and selective DPP -4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes [ J]. Diabet Med ,2010,27(12) : 1409.
  • 10Pratley R E, McCall T, Fleck P R,et al. Alogliptin use in elderly peo- ple: a pooled analysis from phase 2 and 3 studies [ J]. J Am Geriatr Soc ,2009,57 ( 11 ) :2011.

引证文献3

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部